Business
Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy
Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1, an unprecedented outcome Technology is seen as transformative in increasing the effectiveness of treatment for a wide range of cancers CHICAGO, ...
About this update from Actuate Therapeutics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1, an unprecedented outcome","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Technology is seen as transformative in increasing the effectiveness of treatment for a wide range of cancers","length":109,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":238,"olType":false},{"type":"text","content":"CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / August 25, 2025 / Vexing challenges await cancer researchers every day -- not just in finding new molecules -- but now, increasingly, in finding new ways to make tumors more vulnerable to existing drugs.","length":254,"tagName":"p"},{"type":"text","content":"Tumors have their own defense mechanisms, designed to thwart therapeutic intruders, and the immune system is often unable to mount an effective response.","length":153,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":584,"height":313,"url":"https://media.zenfs.com/en/accesswire.ca/0967b903b7c4aac6e836b3bd9025021a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3FyDhBJPLTr_A7FV9mAcMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxNTtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/0967b903b7c4aac6e836b3bd9025021a","width":584,"height":313}}},{"type":"text","content":"Dozens of companies are working in this area but Actuate Therapeutics (NASDAQ:ACTU) reports it has made more progress than any other, especially when it comes to difficult-to-treat tumors like metastatic ductal pancreatic cancer.","length":229,"tagName":"p"},{"type":"text","content":"One current standard of care for this diagnosis is gemcitabine combined with nab-paclitaxel, a drug developed 13 years ago by Celgene as Abraxane (now owned by Bristol-Myers Squibb (BMY). It won FDA approval after a Phase 3 trial showed that the combination (generically called GnP) increased overall survival of metastatic pancreatic cancer patients by nearly two months (8.5 vs. 6.7) compared to gemcitabine alone.","length":416,"tagName":"p"},{"type":"text","content":"GnP still remains one of the most widely prescribed front-line chemotherapeutics for pancreatic cancer, with $1.8 billion in sales last year.","length":141,"tagName...